Related Experiment Video
Updated: Apr 30, 2026

Transport Properties of Ibuprofen Encapsulated in Cyclodextrin Nanosponge Hydrogels: A Proton HR-MAS NMR Spectroscopy Study
Published on: August 15, 2016
Efficient ibuprofen delivery from anhydrous semisolid formulation based on a novel cross-linked silicone polymer
Hyder Aliyar1, Robert Huber1, Gary Loubert1
1Dow Corning Corporation, Healthcare Industry, Pharmaceutics, Midland, Michigan 48686.
Abstract:
The use of silicone as a primary polymer in topical semisolid pharmaceutical formulations is infrequent. Recent development of novel silicone materials provides an opportunity to investigate their drug delivery efficiencies. In this study, an anhydrous semisolid formulation was prepared using a novel cross-linked silicone polymer network swollen in isododecane. Similar formulations were prepared using petrolatum, an acrylic, or a cellulose polymer. All formulations contained 5% ibuprofen (IBP). In vitro permeability was evaluated for all formulations and a commercial product using human cadaver epidermis. The silicone formulation delivered IBP more efficiently than all other formulations in terms of flux, cumulative amount, and percent drug release. The silicone formulation showed the maximum flux of 85.9 μg . cm(-2) . h(-1) and a cumulative IBP release of 261.6 μg in 8 h, whereas the benchmark showed 20.1 μg . cm(-2) . h(-1) and 30.9 μg, respectively. An in vivo study conducted on rats showed calculated blood AUCs of 59.2 and 17.6 μg . h/g (p < 0.003) for the silicone formulation and the benchmark, respectively. The IBP in excised rat skin was 264 ± 59 μg/g for the silicone formulation and 102 ± 5 μg/g for the benchmark. The results obtained from the in vitro and in vivo studies demonstrate efficient topical IBP delivery by the silicone formulation.
Related Concept Videos
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Modified-Release Drug Delivery Systems: Rate-Programmed I
Oral Drug Delivery Systems: Delayed-Release Systems
Oral Drug Delivery Systems: Continuous-Release Systems
Modified-Release Drug Delivery Systems: Drug Release Characteristics
Modified-Release Drug Delivery Systems: Rate-Programmed II

